 |
20 Diseases |  |
1 Trial |
|
1 Trial |  |
137 News |  |
| 12» |
- | varlitinib (ASLAN001) / ASLAN Pharma
Preclinical, Journal: Differential Protein Expression in Response to Varlitinib Treatment in Oral Cancer Cell Line: an In Vitro Therapeutic Approach. (Pubmed Central) - Apr 23, 2024
Oral cancer cells show proteome shift based on varlitinib treatment compared to corresponding controls. Our data suggest candidature of varlitinib as a potent therapeutic agent and BiP, PDIA1, HSP7C, VIME, and ?-Actin as complementary/prognostic markers of OSCC.
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Enrollment change, Combination therapy, Metastases: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients (clinicaltrials.gov) - Nov 13, 2023
P1/2, N=27, Completed, Sponsor: Yonsei University
Our data suggest candidature of varlitinib as a potent therapeutic agent and BiP, PDIA1, HSP7C, VIME, and ?-Actin as complementary/prognostic markers of OSCC. Active, not recruiting --> Completed | N=62 --> 27
- | Journal: Differences in sensitivity to new therapies between primary and metastatic breast cancer: A need to stratify the tumor response? (Pubmed Central) - Feb 27, 2023
P2a/2b
The therapeutic responses differed across tumors' locations; the magnitude of the differences of responses across the tumors' locations were drug-dependent. Stratified analysis of the response by tumor location improved drug comparisons and is a powerful tool to understand TL heterogeneity.
- | Vumon (teniposide) / BMS
Journal, Tumor Mutational Burden, Pan tumor: The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective. (Pubmed Central) - Dec 9, 2022
The tumor-promoting activity of YAP1 is attributed to the activation of TGF-β, Hedgehog, and KRAS signaling pathways. AZD2858 and varlitinib might be effective in cancer patients with high YAP1 expression.
- | varlitinib (ASLAN001) / ASLAN Pharma
Journal: Inhibiting EGFR/HER-2 ameliorates neuroinflammatory responses and the early stage of tau pathology through DYRK1A. (Pubmed Central) - Nov 8, 2022
However, in 6-month-old tau-overexpressing PS19 mice, varlitinib only significantly diminished astroglial activation and tau phosphorylation at Thr212/Ser214. Taken together, our findings suggest that varlitinib has therapeutic potential for LPS- and tau-induced neuroinflammatory responses and the early stages of tau pathology.
- ||||| varlitinib (ASLAN001) / ASLAN Pharma, capecitabine / Generic mfg.
Clinical: Varlitinib plus capecitabine in second-line advanced biliary tract #cancer: a randomized, #phaseII study (TreeTopp) - What is the next more promising combination? @OncoAlert @myESMO @cczielinski @PaoloBossi6 https://t.co/ont8dUukX8 (Twitter) - Oct 29, 2022
- varlitinib (ASLAN001) / ASLAN Pharma
Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13) (Poster Area, Hall 4) - Jul 28, 2022 - Abstract #ESMO2022ESMO_3002;
Conclusions Varlitinib combined with paclitaxel revealed manageable toxicities and antitumor activity in patients with EGFR/HER2 co-expressing AGC who progressed after first-line chemotherapy. Updated outcomes for ongoing patients and biomarker analysis will be presented.
- | varlitinib (ASLAN001) / ASLAN Pharma
Journal: Evaluation of anti-EGFR potential of quinazoline derivatives using Molecular docking: An in silico approach. (Pubmed Central) - Jul 8, 2022
GOLD demonstrated varlitinib to be the best inhibitor with highest fitness score of 109 while AutoDock Vina revealed imatinib as the potent ligand with least binding energy of -10.9 Kcal/mol. Most stable hydrogen bonds observed by GOLD and maximum number of hydrophobic contacts along with strong ionic interaction exhibited by varlitinib through both software has led us to conclude varlitinib as the most potent EGFR inhibitor in the studied group.
- | varlitinib (ASLAN001) / ASLAN Pharma
New P1/2 trial, Combination therapy, Metastases: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients (clinicaltrials.gov) - Jun 2, 2022
P1/2, N=62, Active, not recruiting, Sponsor: Yonsei University
- || varlitinib (ASLAN001) / ASLAN Pharma
P1 data, Clinical Trial,Phase I, Journal: Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors. (Pubmed Central) - Apr 13, 2022
P2
Subcutaneous trastuzumab can be added safely to varlitinib and paclitaxel. This combination is currently being evaluated as neoadjuvant therapy in HER2+ breast cancer (NCT02396108).
- || varlitinib (ASLAN001) / ASLAN Pharma
Clinical, P2 data, Journal: Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp). (Pubmed Central) - Mar 25, 2022
In patients with advanced biliary tract cancer, second-line treatment with varlitinib plus capecitabine was well tolerated but did not improve efficacy versus capecitabine alone. A PFS benefit was suggested in female patients and those with gallbladder cancer.
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Enrollment change, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Feb 15, 2022
P2/3, N=52, Completed, Sponsor: Aslan Pharmaceuticals
A PFS benefit was suggested in female patients and those with gallbladder cancer. Active, not recruiting --> Completed | N=400 --> 52
- varlitinib (ASLAN001) / ASLAN Pharma
Varlitinib in combination with gemcitabine and cisplatin for treatment-naïve advanced biliary tract cancer. (In-Person Only | Level 1, West Hall; Online Only) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_786;
P1b/2
Active, not recruiting --> Completed | N=400 --> 52 Varlitinib combined with gemcitabine plus cisplatin was well tolerated and associated with preliminary anti-tumor activity in patients with treatment-naïve advanced BTC.
- | Truseltiq (infigratinib) / BridgeBio, Pfizer, varlitinib (ASLAN001) / ASLAN Pharma
Biomarker, Journal: Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor. (Pubmed Central) - Sep 15, 2021
The upregulation of the ErbB family by EZH2 appears to contribute to infigratinib resistance. The combination of infigratinib and varlitinib showed a potent antitumour effect and did not result in additional toxicity, warranting further clinical investigation.
- ||||| varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Combination therapy, Metastases: TreeTopp: Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Aug 3, 2021
P2/3, N=151, Completed, Sponsor: Aslan Pharmaceuticals
The combination of infigratinib and varlitinib showed a potent antitumour effect and did not result in additional toxicity, warranting further clinical investigation. Active, not recruiting --> Completed
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Apr 28, 2021
P1, N=60, Active, not recruiting, Sponsor: National Cancer Centre, Singapore
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Jun 2020 --> Jun 2021 | Trial primary completion date: Jun 2020 --> Jun 2021
- | varlitinib (ASLAN001) / ASLAN
Preclinical, Journal: In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines. (Pubmed Central) - Mar 31, 2021
Aspartate metabolite level was correlated with varlitinib response. Combination of varlitinib with targeted drug or cytotoxic drug was recommended.
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial termination, Combination therapy, Metastases: Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment na (clinicaltrials.gov) - Jan 14, 2021
P1b/2, N=204, Terminated, Sponsor: Aslan Pharmaceuticals
Combination of varlitinib with targeted drug or cytotoxic drug was recommended. Active, not recruiting --> Terminated; Sponsor decided to terminate the study and not proceed to Phase 2.
- varlitinib (ASLAN001) / ASLAN, Herceptin (trastuzumab) / Roche
[VIRTUAL] Phase Ib trial of varlitinib plus weekly paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer (AGC). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_184;
The combination of varlitinib 300mg bid and weekly paclitaxel 80mg showed manageable safety profiles and determined as RP2D. Currently, multi-site phase 2 part is now underway.
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Combination therapy, Metastases: Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment na (clinicaltrials.gov) - Nov 19, 2020
P1b/2, N=204, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Currently, multi-site phase 2 part is now underway. Recruiting --> Active, not recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Metastases: Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Nov 19, 2020
P2a, N=62, Completed, Sponsor: Aslan Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Herceptin (trastuzumab) / Roche
[VIRTUAL] Targeted therapies: How can CT imaging improve evaluations and help understand mechanism of drug action? () - Apr 29, 2020 - Abstract #ASCO2020ASCO_2874;
P2a/2b
The stratification of changes provides new insights into responses of targeted therapies and more accurate drug comparisons. The stratification is a promising approach to better understand therapy mechanisms of action behind tumor heterogeneity.
- varlitinib (ASLAN001) / ASLAN, capecitabine / Generic mfg.
[VIRTUAL] Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC). (Poster Board 205) - Feb 27, 2020 - Abstract #ASCO2020ASCO_483;
P2/3
V+C is well tolerated but did not improve ORR, PFS or OS vs. P+C in 2L advanced BTC. Exploratory analyses suggested that patients with GBC and female patients achieved comparatively higher median PFS with V+C vs.
- || varlitinib (ASLAN001) / ASLAN
Varlitinib Misses PFS, ORR Endpoints in Biliary Tract Cancer #gicsm https://t.co/fde7pphDNG (Twitter) - Jan 6, 2020
- | varlitinib (ASLAN001) / ASLAN
Journal: Doxorubicin and Varlitinib Delivery by Functionalized Gold Nanoparticles Against Human Pancreatic Adenocarcinoma. (Pubmed Central) - Oct 28, 2019
This study highlights the promising potential of PEGAuNPs for targeted delivery of therapeutic drugs into human cells, enhancing the antitumor growth-inhibition effect on cancer cells, and decreasing the toxicity against normal cells. In cancer therapy, the present approach based on PEGAuNP functionalization can be further explored to increase drug targeting efficiency and to reduce side effects.
- Herceptin (trastuzumab) / Roche
The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location (Exhibition area) - Sep 17, 2019 - Abstract #ESMOAsia2019ESMO_ASIA_416;
P2a/2b
For a fair comparison, the proportion of tumor at each tumor location must be balanced between arms. The stratification of the therapeutic response can be used for assessing new therapies, helping designing cocktails or refining drug’s indications.Legal entity responsible for the study: Median Technologies/Aslan Pharmaceuticals.
- varlitinib (ASLAN001) / ASLAN
A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumours (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_1495;
P1
Durable response in HER2 positive OCCC was seen and warrants further investigation. Clinical trial identification: NCT02435927.
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Metastases: Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Feb 15, 2019
P2a, N=68, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Clinical trial identification: NCT02435927. Recruiting --> Active, not recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment change, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Jan 10, 2019
P2/3, N=400, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Recruiting --> Active, not recruiting N=40 --> 400
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion date, Trial primary completion date, Metastases: Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jan 10, 2019
P2a, N=68, Recruiting, Sponsor: Aslan Pharmaceuticals
N=40 --> 400 Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Mar 2020
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Trial completion date, Combination therapy, Metastases: TreeTopp: Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Dec 31, 2018
P2/3, N=490, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Trial completion date: Jun 2019 --> Jun 2020 | Trial primary completion date: Dec 2018 --> Mar 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2022
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment change, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Sep 14, 2018
P1, N=60, Recruiting, Sponsor: National Cancer Centre, Singapore
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2022 N=18 --> 60
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Sep 5, 2018
P2/3, N=40, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
N=18 --> 60 Recruiting --> Active, not recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion date, Trial primary completion date, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Aug 22, 2018
P1, N=18, Recruiting, Sponsor: National Cancer Centre, Singapore
Recruiting --> Active, not recruiting Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Enrollment change, Trial completion date, Metastases: A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - Jun 28, 2018
P1, N=24, Completed, Sponsor: Aslan Pharmaceuticals
Trial completion date: Jun 2018 --> Jun 2020 | Trial primary completion date: Jun 2018 --> Jun 2020 Active, not recruiting --> Completed | N=42 --> 24 | Trial completion date: Nov 2019 --> Jun 2018
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TreeTopp: Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jun 6, 2018
P2/3, N=490, Recruiting, Sponsor: Aslan Pharmaceuticals
Active, not recruiting --> Completed | N=42 --> 24 | Trial completion date: Nov 2019 --> Jun 2018 Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Jul 2019
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion date, Metastases: Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jun 2, 2018
P2a, N=68, Recruiting, Sponsor: Aslan Pharmaceuticals
Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Jul 2019 Trial completion date: Dec 2018 --> Jun 2019
- | varlitinib (ASLAN001) / ASLAN Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P1 trial, Metastases: Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 17, 2018
P1b, N=22, Recruiting, Sponsor: National University Hospital, Singapore
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial primary completion date, Combination therapy: ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin (clinicaltrials.gov) - Feb 5, 2018
P1, N=18, Recruiting, Sponsor: National Cancer Centre, Singapore
Trial completion date: Dec 2018 --> Jun 2019 Trial primary completion date: Dec 2017 --> Jun 2018
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment open, Metastases: Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jan 23, 2018
P2a, N=25, Recruiting, Sponsor: Aslan Pharmaceuticals
Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine (clinicaltrials.gov) - Jan 10, 2018
P1, N=31, Completed, Sponsor: Aslan Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Completed | N=24 --> 31 | Trial primary completion date: Dec 2017 --> Jun 2017
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion, Enrollment change, Metastases: ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy (clinicaltrials.gov) - Jan 10, 2018
P2a, N=32, Completed, Sponsor: Aslan Pharmaceuticals
Recruiting --> Completed | N=24 --> 31 | Trial primary completion date: Dec 2017 --> Jun 2017 Recruiting --> Completed | N=25 --> 32
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment closed, Metastases: A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours (clinicaltrials.gov) - Jan 10, 2018
P1, N=42, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Recruiting --> Completed | N=25 --> 32 Recruiting --> Active, not recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial completion: Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib (clinicaltrials.gov) - Jan 10, 2018
P1, N=6, Completed, Sponsor: Aslan Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Completed
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment open, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Dec 11, 2017
P2/3, N=40, Recruiting, Sponsor: Aslan Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma
New P1 trial: Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib (clinicaltrials.gov) - Dec 10, 2017
P1, N=6, Recruiting, Sponsor: Aslan Pharmaceuticals
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment open, Combination therapy, Metastases: TreeTopp: Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Oct 27, 2017
P2/3, N=482, Recruiting, Sponsor: Aslan Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | varlitinib (ASLAN001) / ASLAN Pharma, Herceptin (trastuzumab) / Roche
Trial completion, Trial primary completion date, Combination therapy: Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab (clinicaltrials.gov) - Oct 17, 2017
P2a/2b, N=200, Completed, Sponsor: Aslan Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> May 2016
- | varlitinib (ASLAN001) / ASLAN Pharma
New P2a trial, Metastases: Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer (clinicaltrials.gov) - Jul 26, 2017
P2a, N=25, Not yet recruiting, Sponsor: Aslan Pharmaceuticals
- | varlitinib (ASLAN001) / ASLAN Pharma
Trial initiation date, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Jun 7, 2017
P2/3, N=40, Not yet recruiting, Sponsor: Aslan Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Feb 2017 --> May 2016 Initiation date: Jun 2017 --> Sep 2017